全文获取类型
收费全文 | 3485篇 |
免费 | 259篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 130篇 |
妇产科学 | 64篇 |
基础医学 | 409篇 |
口腔科学 | 50篇 |
临床医学 | 350篇 |
内科学 | 867篇 |
皮肤病学 | 35篇 |
神经病学 | 289篇 |
特种医学 | 146篇 |
外科学 | 588篇 |
综合类 | 19篇 |
一般理论 | 3篇 |
预防医学 | 265篇 |
眼科学 | 92篇 |
药学 | 240篇 |
中国医学 | 3篇 |
肿瘤学 | 170篇 |
出版年
2021年 | 50篇 |
2020年 | 36篇 |
2019年 | 37篇 |
2018年 | 72篇 |
2017年 | 41篇 |
2016年 | 37篇 |
2015年 | 54篇 |
2014年 | 61篇 |
2013年 | 142篇 |
2012年 | 142篇 |
2011年 | 146篇 |
2010年 | 95篇 |
2009年 | 91篇 |
2008年 | 203篇 |
2007年 | 208篇 |
2006年 | 199篇 |
2005年 | 172篇 |
2004年 | 191篇 |
2003年 | 185篇 |
2002年 | 191篇 |
2001年 | 46篇 |
2000年 | 46篇 |
1999年 | 56篇 |
1998年 | 45篇 |
1997年 | 41篇 |
1996年 | 21篇 |
1995年 | 35篇 |
1994年 | 22篇 |
1993年 | 25篇 |
1992年 | 30篇 |
1991年 | 47篇 |
1990年 | 35篇 |
1989年 | 45篇 |
1988年 | 38篇 |
1987年 | 42篇 |
1986年 | 41篇 |
1985年 | 51篇 |
1984年 | 57篇 |
1983年 | 72篇 |
1982年 | 55篇 |
1981年 | 60篇 |
1980年 | 50篇 |
1979年 | 33篇 |
1978年 | 32篇 |
1977年 | 38篇 |
1976年 | 33篇 |
1975年 | 28篇 |
1973年 | 25篇 |
1972年 | 23篇 |
1971年 | 22篇 |
排序方式: 共有3755条查询结果,搜索用时 31 毫秒
1.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
2.
There is a sharp difference in how one views TCR structure–function–behaviour dependent on whether its recognition of major histocompatibility complex‐encoded restriction elements (R) is germline selected or somatically generated. The generally accepted or Standard model is built on the assumption that recognition of R is by the V regions of the αβ TCR, which is not driven by allele specificity, whereas the competing model posits that recognition of R is allele‐specific. The establishing of allele‐specific recognition of R by the TCR would rule out the Standard model and clear the road to a consideration of a competing construct, the Tritope model. Here, the case for allele‐specific recognition (germline selected) is detailed making it obvious that the Standard model is untenable. 相似文献
3.
4.
5.
6.
The craft of surgery has always relied on the use of instruments. Innovations in surgery have paralleled innovations in instrumentation.
Advances in surgical instrumentation continue today and have enabled huge strides in surgical procedures and outcomes during
this generation. Computers and related technology are now changing the interface between the surgeon and the patient, and
are poised to improve patient outcomes by enhancing the surgeon’s skills and training. The application of computer enhanced
telemanipulators, or “robots”, may specifically enhance operations, for example Heller myotomy, that require good visualization
and precise careful dissection of delicate structures. This review covers the pathophysiology of achalasia and its history
of medical and surgical treatment, leading to modern robotic telesurgical approaches. Improvements in outcome from medical
to standard surgical to robotic telesurgical approaches are discussed. Current operative technique for robotic telesurgical
treatment of achalasia is described and the authors conclude with a glimpse of where, in the future, current research endeavors
will lead us in the treatment of achalasia. 相似文献
7.
8.
Antimurine antibody formation following OKT3 therapy 总被引:1,自引:0,他引:1
T J Schroeder M R First M E Mansour P E Hurtubise S Hariharan F C Ryckman R Munda D B Melvin I Penn W F Ballistreri 《Transplantation》1990,49(1):48-51
OKT3 is an IgG2a murine monoclonal antibody directed against the CD3 antigen receptor of human T lymphocytes. A major concern with OKT3 treatment in solid organ transplant recipients is the development of antimouse antibody, which may preclude retreatment with this agent. We have administered OKT3 on 215 occasions (150 renal, 34 hepatic, 26 cardiac, 5 pancreatic) in 179 patients between April 1982 and December 1988. The mean duration of treatment was 10.5 days (range, 2-22 days). Antimouse antibody data were analyzed on the most recent 133 treatment courses where the antibody status was available pretreatment. Determination of antimouse antibody production was elicited by ELISA technology at days 0, 7, 14, and 28 of OKT3 treatment. Patients were categorized according to the antibody response as follows: (a) absence of antibody; (b) low titer (1:100); or (c) high titer (greater than or equal to 1:1000). Our earlier experience has demonstrated that retreatment with OKT3 is successful in groups a and b. The development of antimurine antibodies was analyzed with regard to the following parameters: (1) The duration of OKT3 treatment; (2) treatment type (prophylactic, primary, or secondary); (3) primary treatment or retreatment; (4) concomitant immunosuppressive regimen (double or triple therapy); (5) dosage of concomitant immunosuppressive drugs; and (6) transplant organ type. The following results were obtained. (1) Duration of treatment had no effect on antibody production (11.0 days in antibody negative and 10.0 days in antibody positive). (2) There was no difference in antibody formation rates for the first treatment of OKT3 when it was used as prophylaxis (26%), primary (19%), or secondary (27%) therapy. (3) Antibody formation rate with first treatment was 29%; with retreatment, patients who were antibody negative following first treatment became positive in 28% of cases, and retreated patients who were low titer positive following first treatment converted to high titer in 57% of cases. (4) Antibody formation was higher in patients receiving double immunosuppressive therapy (36%) than in those receiving triple immunosuppressive therapy (21%) during OKT3 treatment. (5) Concomitant immunosuppression was lower in the antibody-positive group during OKT3 therapy: steroids, 61 mg/day vs. 52 mg/day; azathioprine, 89 mg/day vs. 66 mg/day; CsA, 317 mg/day vs. 186 mg/day. (6) Antibody formation rates were lower in non-renal transplants following first treatment with OKT3 (liver 17%, heart 17%, kidney 28%); this reflects the higher doses of concomitant immunosuppressive therapy used in nonrenal transplants.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
9.
10.